Vidac Pharma Holding Plc
0.37
EUR
-0.01
(-2.65%)
ISIN
GB00BM9XQ619
Return %
Stock
S&P 500
1Y
- -
13.14
3Y
- -
80.78
5Y
- -
67.74
Capital Structure
GBP
•
in mil. unless spec.Working Capital
GBP
•
in mil. unless spec.Growth Rates
GBP
•
in mil. unless spec.Semi-annual Revenue
GBP
•
in mil. unless spec.Semi-annual Earnings Per Share
GBP
•
in mil. unless spec.Semi-annual Dividends Per Share
GBP
•
in mil. unless spec.Company Description
- CEO
- Max Herzberg
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- London United Kingdom
- IPO Date
- Mar 29, 2023
- Website
- vidacpharma.com
- Similar Companies
- Business
- Vidac Pharma Holding Plc is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes first-in-class oncology and dermatology therapeutics designed to selectively induce apoptosis in hyper-glycolytic cancer cells. The company operates through proprietary drug discovery platforms targeting the Warburg effect by modulating the interaction between Hexokinase 2 (HK2) and the Voltage-Dependent Anion Channel (VDAC) on mitochondrial membranes. Its core product pipeline comprises VDA-1102 (tuvatexib), a lead first-in-class small molecule HK2 modulator in Phase 2b clinical development as a topical ointment for actinic keratosis and in Phase 2 clinical trials for cutaneous T-cell lymphoma, with additional systemic intravenous formulations under development; VDA-1275, an advanced next-generation new chemical entity in preclinical evaluation for the treatment of multiple solid tumor types both as monotherapy and in combination with standard chemotherapeutic agents; and preclinical discovery programs applying the HK2-VDAC metabolic checkpoint technology to hyper-proliferative autoimmune and inflammatory indications, including psoriasis. Recent corporate developments include the completion of patient visits in the Phase 2b clinical trial of VDA-1102 for advanced actinic keratosis following European Medicines Agency clinical trial approval; the strategic expansion of its research platform beyond oncology with the launch of an in vivo preclinical development program in psoriasis; the integration of its planned French operating affiliate, Eutopos Pharma, into the Quest for Health biotech accelerator to broaden European operations; the expansion of public equity trading across German exchange venues, including XETRA and the Düsseldorf Primary Market; and key governance updates including executive technical appointments and the establishment of long-term employee incentive plans. Founded in 2012, Vidac Pharma Holding Plc is headquartered in London, United Kingdom, and conducts primary research and development operations through its operating subsidiary, Vidac Pharma Ltd., located in Jerusalem, Israel.